Leaky gut, microbiota, and cancer: An incoming hypothesis

Journal of Clinical Gastroenterology

Volumn 48, Issue , 2014, Pages S62-S66

  Saggioro, Alfredo ^a  

^a OSPEDALE DELL'ANGELO   (Italy)

Author keywords

cancer; Functional medicine; Inflammation; Pathogenesis

Indexed keywords

BACTERIAL TOXIN; CYTOKINE;

ANAEROBIC BACTERIUM; AUTOIMMUNE DISEASE; BACTERIAL GROWTH; BACTERIAL STRAIN; CELIAC DISEASE; CHRONIC DISEASE; COLORECTAL CARCINOMA; CONFERENCE PAPER; DISEASE ASSOCIATION; HUMAN; HYPOTHESIS; INFLAMMATION; INTESTINE; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE MUCOSA; MICROFLORA; MUCOSAL IMMUNITY; NEOPLASM; NONHUMAN; PATHOGENESIS; RISK FACTOR; TIGHT JUNCTION; ANIMAL; BACTERIAL TRANSLOCATION; BACTERIUM; CLASSIFICATION; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; PERMEABILITY;

ANIMALS; BACTERIA; BACTERIAL TRANSLOCATION; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; MICROBIOTA; NEOPLASMS; PERMEABILITY; RISK FACTORS; TIGHT JUNCTIONS;

EID: 84916618416     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000255     Document Type: Conference Paper

References (65)

1. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308: 1635-1638.
2. Candela M, Guidotti M, Fabbri A, et al. Human intestinal microbiota: cross-talk with the host and its potential role in colorectal cancer. Crit Rev Microbiol. 2011;37:1-14.
3. Reddy BS, Narisawa T, Wright P, et al. Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. Cancer Res. 1975;35:287-290.
4. Sacksteder MR. Occurrence of spontaneous tumors in the germfree F344 rat. J Natl Cancer Inst. 1976;57:1371-1373.
5. Vannucci L, Stepankova R, Kozakova H, et al. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int J Oncol. 2008;32:609-617.
6. Mestecky J, Bienenstock J, Lamm ME, et al. Mucosal Immunology. 3rd ed. Amsterdam: Elsevier-Academic Press; 2005.
7. Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Ann Rev Immunol. 2010;28: 623-667.
8. Chung H, Kasper DL. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol. 2010;22:455-460.
9. Russell MW, Ogra PL. Mucosal decisions: tolerance and responsiveness at mucosal surfaces. Immunol Invest. 2010;39: 297-302.
10. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799-809.
11. Shan M, Gentile M, Yeiser JR, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science. 2013;342:447-453.
12. Fasano A. Physiological, pathological, and therapeutic implications of zonulin-mediated intestinal barrier modulation: living life on the edge of the wall. Am J Pathol. 2008;173: 1243-1252.
13. Bienenstock J, Collins S. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: psycho-neuroimmunology and the intestinal microbiota: clinical observations and basic mechanisms. Clin Exp Immunol. 2010;160:85-91.
14. Yu QH, Yang Q. Diversity of tight junctions (TJs) between gastrointestinal epithelial cells and their function in maintaining the mucosal barrier. Cell Biol Int. 2009;33:78-82.
15. Laukoetter MG, Bruewer M, Nusrat A. Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol. 2006;22:85-89.
16. Madara JL. Loosing tight functions lessons from the intestine. J Clin Invest. 1989;83:1089-1094.
17. Madara JL, Dharmsathaphorn K. Occluding junction structure- function relationships in a cultured epithelial monolayer. J Cell Biol. 1985;101:2124-2133.
18. Fleming TP, Ghassemifar MR, Sheth B. Junctional complexes in the early mammalian embryo. Semin Reprod Med. 2000; 18:185-193.
19. Furuse M, Tsukita S. Claudins in occluding junctions of humans and flies. Trends Cell Biol. 2006;16:181-188.
20. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest. 2004; 84:282-291.
21. Fasano A, Nataro JP. Intestinal epithelial tight junctions as tar- gets for enteric bacteria-derived toxins. Adv Drug Deliv Rev. 2004;56:795-807.
22. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;2:416-422.
23. Fasano A. Pathological and therapeutical implications of macromolecule passage through the tight junction. In: Cereijido M, Andersom J, eds. Tight Junctions. Boca Raton, FL: CRC; 2001:697-722.
24. MäkeläM, Vaarala O, Hermann R, et al. Enteral virus infections in early childhood and an enhanced type 1 diabetesassociated antibody response to dietary insulin. J Autoimmun. 2006;27:54-61.
25. Mojibian M, Chakir H, Lefebvre DE, et al. Diabetes-specific HLA-DR-restricted proinflammatory T-cell response to wheat polypeptides in tissue transglutaminase antibodynegative patients with type 1 diabetes. Diabetes. 2009;58: 1789-1796.
26. Simpson M, Mojibian M, Barriga K, et al. An exploration of Glo-3A antibody levels in children at increased risk for type 1 diabetes mellitus. Pediatr Diabetes. 2009;10: 563-572.
27. De Palma G, Nadal I, Medina M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 2010;10:63.
28. De Palma G, Cinova J, Stepankova R, et al. Pivotal advance: bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease. J Leukoc Biol. 2010;87:765-768.
29. Dubois PC, van Heel DA. Translational mini-review series on the immunogenetics of gut disease: immunogenetics of coeliac disease. Clin Exp Immunol. 2008;153:162-173.
30. Ou G, Hedberg M, Hörstedt P, et al. Proximal small intestinal microbiota and identification of rod-shaped bacteria associated with childhood celiac disease. Am J Gastroenterol. 2009;104: 3058-3067.
31. Ochoa-Repáraz J, Mielcarz DW, Ditrio LE, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol. 2009;183: 6041-6050.
32. Westall FC. Abnormal hormonal control of gut hydrolytic enzymes causes autoimmune attack on the CNS by production of immune-mimic and adjuvant molecules: a comprehensive explanation for the induction of multiple sclerosis. Med Hypotheses. 2007;68:364-369.
33. Yokote H, Miyake S, Croxford JL, et al. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol. 2008;173:1714-1723.
34. Edwards CJ. Commensal gut bacteria and the etiopathogenesis of rheumatoid arthritis. J Rheumatol. 2008;35:1477-1479.
35. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10:131-144.
36. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124:3-20.
37. Sonier B, Patrick C, Ajjikuttira P, et al. Intestinal immune regulation as a potential diet-modifiable feature of gut inflammation and autoimmunity. Int Rev Immunol. 2009;28: 414-445.
38. Cereijido M, Contreras RG, Flores-Benítez D, et al. New diseases derived or associated with the tight junction. Arch Med Res. 2007;38:465-478.
39. Shen L, Turner JR. Role of epithelial cells initiation and propagation of intestinal inflammation. Eliminating the static: tight junction dynamics exposed. Am J Physiol Gastrointest Liver Physiol. 2006;290:G577-G582.
40. Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev. 2000;173: 89-97.
41. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett. 2004;93:97-108.
42. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclearcytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2004;5:104-112.
43. Petnicki-Ocwieja T, Hrncir T, Liu YJ, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA. 2009;106:15813-15818.
44. Ogra PL. Developmental aspects of the mucosal immune system: role of external environment, mucosal microflora and milk. Adv Exp Med Biol. 2009;639:41-56.
45. Tlaskalova-Hogenova H, Tuckova L, Lodinova-Zadnikova R, et al. Mucosal immunity: its role in defense and allergy. Int Arch Allergy Immunol. 2002;128:77-89.
46. Brandtzaeg P. Update on mucosal immunoglobulin A in gastrointestinal disease. Curr Opin Gastroenterol. 2010;26: 554-563.
47. Hanson LA, Silfverdal SA. The mother's immune system is a balanced threat to the foetus, turning to protection of the neonate. Acta Paediatr. 2009;98:221-228.
48. Kverka M, Burianova J, Lodinova-Zadnikova R, et al. Cytokine profiling in human colostrum and milk by protein array. Clin Chem. 2007;53:955-962.
49. McGuire C, Prinz M, Beyaert R, et al. Nuclear factor kappa B (NF-kB) in multiple sclerosis pathology. Trends Mol Med. 2013;19:604-613.
50. Erstad DJ, Cusack JC Jr. Targeting the NF-kB pathway in cancer therapy. Surg Oncol Clin N Am. 2013;22: 705-746.
51. Marusawa H, Jenkins BJ. Inflammation and gastrointestinal cancer: an overview. Cancer Lett. 2014;345:153-156.
52. McConnell BB, Yang VW. The role of Inflammation in the pathogenesis of colorectal cancer. Curr Colorectal Cancer Rep. 2009;5:69-74.
53. O'Keefe SJ, Ou J, Aufreiter S, et al. Products of the colonic microbiota mediate the effects of diet on colon cancer risk. J Nutr. 2009;139:2044-2048.
54. Wang CZ, Ma XQ, Yang DH, et al. Production of enterodiol from defatted flaxseeds through biotransformation by human intestinal bacteria. BMC Microbiol. 2010;10:115.
55. Velentzis LS, Cantwell MM, Cardwell C, et al. Lignans and breast cancer risk in pre- and post-menopausal women: metaanalyses of observational studies. Br J Cancer. 2009;100: 1492-1498.
56. Chung KT, Stevens SE Jr, Cerniglia CE. The reduction of azo dyes by the intestinal microflora. Crit Rev Microbiol. 1992;18:175-190.
57. Babu SD, Jayanthi V, Devaraj N, et al. Expression profile of mucins (MUC2, MUC5AC and MUC6) in Helicobacter pylori infected pre-neoplastic and neoplastic human gastric epithelium. Mol Cancer. 2006;5:10.
58. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene. 2008;27:234-243.
59. Danaei G, Singh GM, Paciorek CJ, et al. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation. 2013;127:1493-1502.
60. Popkin BM. Understanding global nutrition dynamics as a step towards controlling cancer incidence. Nat Rev Cancer. 2007;7:61-67.
61. Bonow RO, Smaha LA, Smith SC Jr, et al. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation. 2002;106:1602-1605.
62. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol. 2006;100:481-499.
63. Gutowski M, Kowalczyk S. A study of free radical chemistry: their role and pathophysiological significance. Acta Biochim Pol. 2013;60:1-16.
64. Ramos AF, de Fuccio MB, Moretzsohn LD, et al. Cystic fibrosis, gastroduodenal inflammation, duodenal ulcer, and H. pylori infection: the "cystic fibrosis paradox" revisited. J Cyst Fibros. 2013;12:377-383.
65. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des. 2012;18:3831-3858.